Combining Portfolios From Mergers & Acquisitions in Bio/pharmaceutical R&D

Mergers and acquisitions (M&A) are becoming an ever increasing part of business in Bio/pharmaceutical R&D.  M&A can involve the combining of two project portfolios. When the two portfolios are relatively large the process of combination can be a considerable challenge.  We have prepared a whitepaper  “Combining Portfolios From Mergers & Acquisitions in Bio/pharmaceutical R&D” that outlines the steps involved in combining project portfolios of two companies. Here are the topics.

  1. The Challenge of Nomenclature
    a. Determining the titles and definitions for Stages of Work and the Milestones
    b. Developing a common system for naming projects.
    c. Determining or develop a common IT structure for storing project portfolio data.
    d. Developing a method for identifying target and project overlaps from the contributing companies

2. Resolving Overlaps
3. Defining Stages & Milestones and Criteria for Progression
4. Sorting Into Stages
5. Merging Projects and Associated Assets
6. Developing Protocols to Ensure Data Integrity

Io learn more about this whitepaper please go to the section “Whitepapers and Webinars on Portfolio Management from James Samanen Consulting” and look for the whitepaper entitled “Combining Portfolios From Mergers & Acquisitions in Bio/pharmaceutical R&D”.